Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + nab-paclitaxel + nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2600133689Phase 4Completed
- Sponsor
- Fuyang City Cancer Hospital
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, paclitaxel and nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fuyang City Cancer Hospital. Started Jan 2024; status: completed.
02
Drugs
camrelizumabpaclitaxelnedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600133689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133689.